PBP1510 (INN:ULENISTAMAB)

Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells and tumor microenvironment TME. PBP1510 has been designated as an orphan drug by the FDA, EMA, and MFDS in 2021. It is currently undergoing Phase 1/2a clinical trials in the United States and Europe and has recently been granted FDA Fast Track designation.